Charles River Laboratories International (CRL) Earnings Date & Reports

Key Takeaways

• Charles River Laboratories is expected to report its third-quarter 2026 results in early November, following a second quarter that delivered the company's first organic revenue growth since 2023.
• Management has guided for organic revenue to turn positive again in the third quarter, led by accelerating demand in its Discovery and Safety Assessment (DSA) segment.
• The DSA net book-to-bill ratio reached roughly 1.2x in the second quarter — the third consecutive quarter above 1x and its highest level in nearly four years.
• Full-year 2026 guidance was raised in August to organic revenue growth of 0.0% to 1.0% and non-GAAP earnings per share (EPS) of $11.15 to $11.45.
• Reported (GAAP) results remain pressured by divestiture-related losses, with full-year GAAP EPS guidance of $3.05 to $3.35.
• Investors are watching biotech funding trends, non-human primate (NHP) supply costs, and the pace of portfolio divestitures as key swing factors.
• For more on Charles River Laboratories, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to discover AI-driven trading strategies and ideas.

Earnings Context and Why It Matters

Charles River Laboratories, a leading provider of research models and preclinical drug development services, is working through a multi-year reset after biopharmaceutical clients pulled back on early-stage research spending. Its second-quarter 2026 report marked a potential inflection, with total organic revenue rising 0.1% — the first increase since the third quarter of 2023. The upcoming third-quarter report will test whether that momentum is durable, particularly in the DSA segment, which accounts for the majority of revenue. With the company having completed several divestitures to sharpen its portfolio, investors are looking for evidence that the core regulated-testing business can sustain growth and rebuild earnings power.

Earnings Expectations

Heading into the third quarter of 2026, the focus is on whether Charles River can extend its return to organic growth. Management said in August that it expects "incremental organic revenue growth starting in the third quarter," driven by improving demand trends in the Discovery and Safety Assessment (DSA) segment. For the full year, the company raised its organic revenue outlook to growth of 0.0% to 1.0% and its non-GAAP EPS guidance to $11.15 to $11.45, up $0.25 at the midpoint. That implies a meaningful step-up in back-half earnings after a second-quarter non-GAAP EPS of $3.02.

Key metrics investors will watch include the DSA net book-to-bill ratio — which reached roughly 1.2x in the second quarter — and the segment's backlog, reported at about $1.97 billion. Bookings above 1x signal that new orders are outpacing revenue, a leading indicator of future growth. Biotech funding conditions, NHP supply costs, and margin trends across the DSA, Research Models and Services (RMS), and Manufacturing segments will also be closely scrutinized.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking earnings-driven moves in names like Charles River Laboratories, it offers a structured way to surface potential setups and monitor shifting sentiment.

Market Reaction and Investor Sentiment

Sentiment around Charles River has improved alongside signs of a biotech funding recovery, but caution persists. The company's August report beat expectations on non-GAAP EPS and organic growth, yet a GAAP loss and lower GAAP EPS guidance underscored the lingering drag from divestitures. Into the third-quarter report, investors are weighing the improving DSA demand outlook against execution risk tied to the portfolio reshape and constrained academic and government research spending. A clear beat on organic growth and DSA bookings could reinforce the turnaround narrative, while any reversal in demand trends would likely pressure the shares.

Forward Outlook and Key Factors to Monitor

Beyond the third-quarter print, the trajectory of DSA demand will be the central story. The company has pointed to three consecutive quarters with a book-to-bill ratio above 1x, and a sustained reading at or above that level would support continued organic growth into 2027. Watch for commentary on small- and mid-sized biotech funding, which management has described as resilient and broad-based, as well as any signs of renewed spending from large global biopharmaceutical clients.

Margin recovery is another important theme. Management has targeted at least 500 basis points of sequential operating-margin improvement in the second half of the year, aided by divestitures and lower NHP-related costs. Investors should monitor whether the Manufacturing segment's elevated profitability holds and whether RMS can stabilize amid softer North American research-model volumes.

Finally, capital deployment and the remainder of the portfolio reshape matter. With divestitures of the CDMO (contract development and manufacturing organization) and Cell Solutions businesses complete, attention turns to reinvesting proceeds, the $1 billion buyback authorization, and any targeted M&A (mergers and acquisitions) in bioanalysis and in vitro services. These factors will shape both near-term earnings quality and longer-term growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations